600529 Shandong Pharmaceutical Glass
- 24.99
- +0.15+0.60%
Shandong Pharmaceutical Glass News
Shandong Pharmaceutical (600529.SH): List of goods subject to new tariffs imposed by the US in May, not involving the types of products exported by the company to the US
Gelonghui, May 28 | Shandong Pharmaceutical (600529.SH) said on the investor interactive platform that the list of goods subject to new tariffs imposed by the US in May 2024 did not cover the types of products the company exported to the US.
Shandong Pharmaceutical (600529): China's borosilicate products accelerate release performance and steady growth
Incident 1: On the evening of April 22, the company released its 23-year annual report, achieving annual revenue of 4.98 billion yuan, +19.0% year over year; net profit to mother of 780 million yuan, +25.5% year over year; deducted non-net profit of 740 million yuan, +23.1% year over year.
Calculating The Fair Value Of Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Shandong Pharmaceutical GlassLtd fair value estimate is CN¥24.29 With CN¥28.73 share price, Shandong Pharmaceutical GlassLtd appears to be tr
Shandong Pharmaceutical (600529): Borosilicate growth increases gross profit costs, increases profits
Event: Total operating income of 4.982 billion yuan (+18.98%); net profit to mother of 776 million yuan (+25.48%); net profit after deducting non-return to mother of 742 million yuan (+23.07%) was achieved in 2023. 2
Shandong Pharmaceutical Glass (600529): Good performance growth, borosilicate products continue to gain strength
Incident: The company disclosed its 2024 quarterly report, achieving operating income of 1,267 million yuan, an increase of 2.50% year on year; net profit to mother of 221 million yuan, up 32.59% year on year; deducted non-net profit of 210 million yuan, same
Shandong Pharmaceutical Glass (600529): Continuous optimization of product structure and further enhancement of market competitiveness
The company achieved operating income of 4.982 billion yuan in 2023, an increase of 18.98% over the previous year; net profit after deduction was 742 million yuan, an increase of 23.07% over the previous year. Achieving a basic EPS is 1.17 yuan. 20
Shandong Pharmaceutical (600529): Borosilicate emissions have accelerated and profits have improved significantly
The incident described achieving revenue of 4.982 billion yuan in 2023, up 18.98% year on year; attributable net profit of 776 million, up 25.48% year on year; deducted non-net profit of 742 million yuan, up 23.07% year on year
Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next
It's been a sad week for Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529), who've watched their investment drop 11% to CN¥28.48 in the week since the company reported its quarterly result. The
Shandong Pharmaceutical (600529): Excellent cash flow performance, improved profit margin
Incident: The company published its 2023 annual report and 2024 quarterly report. In 2023, we achieved revenue of 4.98 billion yuan +19% year over year, and net profit of 780 million yuan +25% year over year. 2024Q1 Achieving Revenue
Tianfeng Securities released a research report on April 24 stating that it gave Shandong Pharmaceutical (600529.SH) a purchase rating, with a target price of 38.01 yuan. The main reasons for the rating include: 1) strong revenue growth, resonance in the b
Tianfeng Securities released a research report on April 24 stating that it gave Shandong Pharmaceutical (600529.SH) a purchase rating, with a target price of 38.01 yuan. The main reasons for the rating include: 1) strong revenue growth, resonance in the borosilicate industry trends/categories, and optimism for sustainability; 2) further improvement in profitability, excellent capital structure and cash flow management. (Mainichi Keizai Shimbun)
Shandong Pharmaceutical Glass (600529): Class I molded bottles maintained a high growth rate of 24Q1 gross margin
Guide to this report: The company's 2023 annual report and 2014 quarterly report are in line with expectations. The company's first-class molded bottles maintained high growth, driving strong revenue growth, and declining costs of raw materials such as soda ash led to continuous optimization of profitability. Key Investment Points: Maintaining “Growth
Shandong Pharmaceutical (600529) 2023 Annual Report 2024 Quarterly Report Comment: Continuing to be optimistic about China's borosilicate boom, leading racetrack profits can be expected
The company released the 2023 annual report & 2024 quarterly report: achieved revenue of 4.982 billion yuan in 2023, +18.98% year over year; net profit to mother of 776 million yuan, +25.48% year over year; net profit without return to mother
Minsheng Securities released a research report on April 23 stating that it gave Shandong Pharmaceutical (600529.SH) a recommended rating. The main reasons for the rating include: 1) the company released the 2023 annual report & 2024 quarterly report; 2) t
Minsheng Securities released a research report on April 23 stating that it gave Shandong Pharmaceutical (600529.SH) a recommended rating. The main reasons for the rating include: 1) the company released the 2023 annual report & 2024 quarterly report; 2) the core product molded bottle & brown bottle grew rapidly; 3) abundant cash flow and completed profit commission and incentive extraction after meeting performance standards; 4) the high demand for borosilicate molded bottles continued to contribute to increased growth with overseas products; 5) refined management reduced costs and increased efficiency, and the 2024 soda price reduction released profit elasticity. (Mainichi Keizai Shimbun)
Shandong Pharmaceutical (600529): Borosilicate industry trends+expansion category resonance, falling raw fuel prices drive profit recovery
The company's net profit returned to mother in '23 was 776 million yuan, up 25.48% year on year. The company published the annual report for '23 and the quarterly report for '24, and achieved revenue/net profit to mother of 49.82/776 million yuan for the full year of '23, year over year
SHANDONG PHARMACEUTICAL GLASS(600529):MOLDED BOTTLES IN NEUTRAL BOROSILICATE GLASS FACING ACCELERATING IMPROVEMENTS IN BUSINESS CLIMATE;VALUATIONS HAVE LARGE UPSIDE ON SOLID DEMAND
2023 and 1Q24 results miss our expectationsShandong Pharmaceutical Glass announc
Shandong Pharmaceutical (600529): Borosilicate boom accelerates, demand is evergreen, and valuation space is broad
2023 &1Q24 was slightly lower than our expectations. The company announced 2023&1Q24 results: revenue in 2023 +19% to 5 billion yuan, and net profit to mother +25% year-on-year to 776 million yuan. which
Shandong Pharmaceutical Group (600529): Incentives and fees have certain disturbances to focus on strong growth momentum
The company disclosed the annual report for '23 and the quarterly report for '24, with 23FY revenue of 4.98 billion yuan, yoy +19%, net profit attributable to mother of 780 million, yoy +25%, net profit deducted from non-mother of 740 million, yoy +23%; single
Shandong Pharmaceutical (600529.SH): Net profit of 221 million yuan in the first quarter increased 32.59% year-on-year
Gelonghui, April 22丨Shandong Pharmaceutical (600529.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,267 million yuan, up 2.50% year on year; net profit attributable to shareholders of listed companies was 221 million yuan, up 32.59% year on year; after deducting non-net profit of 210 million yuan, up 36.14% year on year; basic earnings per share were 0.33 yuan.
Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529) Investors Are Less Pessimistic Than Expected
It's not a stretch to say that Shandong Pharmaceutical Glass Co.Ltd's (SHSE:600529) price-to-earnings (or "P/E") ratio of 28.6x right now seems quite "middle-of-the-road" compared to the market in Ch
Shandong Pharmaceutical (600529): Demand is rising, costs are declining, and going overseas is accelerating
Shandong Pharmaceutical: The main products of the domestic pharmaceutical packaging industry leader company include molded bottles, brown bottles, ampoules, control bottles, butyl rubber stoppers, plastic bottles with aluminum-plastic caps, etc., and more than 1,000 types of specifications, used in various pharmaceuticals, health products, cosmetics, etc.
Analysis
Price Target
No Data
